And if you talk to MD�s that has been involved in the AML-trial with Histamine Dihydrochloride (Ceplene) + IL-2 you will get some really interesting and (of course) positive comments.
The drug combination creates uniqe results.
Read the report and read the release by Maxim. Study design and doses are different. Chicago study showed that Il-2 didn't work how they dosed it. Doesn't prove that the Maxim dosing of Il-2 didn't cause the effect. Very simple folks - read the reports and then tell me they are the same.
There will be an interim report (regarding Ceplene and EMEA) next days.
Approval will be late Q4 07 or Q1 08 (which is more probably)
Jack Talley mentioned at shareholder meeting, that
everything is on the way and EMEA already
Approval in late -07 at best but more likely early -08 if everything on track and following the reg pathway in the centralized procedure at EMEA. Oral hearing will be very interesting. If you listen to the webcast yesterday you�ll get the picture. CEO sounds _very_ confident... and they met with EMEA just a few days ago!
But HEY - there will be tons of nice stock triggers already during the upcoming weeks and months. We will see FPI in Azixa ph II/III trial and that will trigger milestone payments. There will be clinical data presented at ASCO June 1-5. We could also get a update on the VDA drug 2407.